多形性膠質母細胞瘤治療市場規模、佔有率、成長分析，按治療類型、最終用戶、地區分類 - 產業預測，2024-2031

2022年，多形性膠質母細胞瘤治療的全球市場規模為24.6億美元，從2023年的27億美元成長到2031年的56.6億美元，在預測期內（2024-2031年）預計將以複合年成長率成長。

由於膠質母細胞瘤病例的快速增加以及對研究和開發的日益關注，預計多形性膠質母細胞瘤治療市場將顯著成長。全球癌症觀察站的令人震驚的統計數據顯示，2020 年腦癌死亡人數超過 251,000 人，確診人數超過 308,000 人，大型製藥企業正在加大產品平臺。根據世界衛生組織 2021 年發布的證據，腦癌病例超過 245,000 例，增加了對有效治療方案的需求。然而，市場面臨障礙，包括高昂的治療成本以及開發針對這種侵襲性癌症的有效治療方法的挑戰。然而，在個人化醫療的進步和有希望的臨床試驗結果的推動下，免疫療法、標靶治療和創新聯合治療的機會比比皆是。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特分析與影響
  • 競爭公司之間的敵對關係
  • 替代品的威脅
  • 買方議價能力
  • 新進入者的威脅
  • 供應商的議價能力

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 監管環境
• 專利分析
• 案例研究

按治療類型分類的多形性膠質母細胞瘤治療市場規模

• 市場概況
• 化療
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • 其他
• 放射治療
  • 外部放射治療（EBRT）
  • 放射線治療
• 標靶治療
  • 單株抗體
  • 蛋白酪氨酸激酶抑制劑
• 免疫療法
  • 查核點抑制劑
  • 疫苗治療
• 腫瘤治療電場（TTF）療法
• 外科手術
  • 開顱手術
  • 切片檢查

多形性膠質母細胞瘤治療市場規模：依最終用戶分類

• 市場概況
• 醫院
• 診所
• 門診手術中心
• 調查機構

按地區分類的多形性膠質母細胞瘤治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Roche Holding AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Sanofi SA
• Bayer AG
• AstraZeneca plc
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ipsen SA
• Sumitomo Dainippon Pharma Co., Ltd.
• Karyopharm Therapeutics Inc.

結論和建議

Global Glioblastoma Multiforme Treatment Market size was valued at USD 2.46 billion in 2022 and is poised to grow from USD 2.70 billion in 2023 to USD 5.66 billion by 2031, growing at a CAGR of 9.7% during the forecast period (2024-2031).

The glioblastoma multiforme treatment market is poised for substantial growth, driven by a surge in glioblastoma cases and a heightened focus on research and development. Major pharmaceutical companies are bolstering their product pipelines, responding to the alarming statistics from the Global Cancer Observatory, which noted over 251,000 deaths and 308,000 diagnoses of brain cancers in 2020. Added evidence from the WHO in 2021 highlighted more than 245,000 occurrences of such tumors, amplifying the need for effective treatment options. However, the market faces hurdles, including high treatment costs and the challenge of developing effective therapies for this aggressive cancer. Nevertheless, opportunities abound in immunotherapy, targeted treatments, and innovative combinations, fueled by advancements in personalized medicine and promising clinical trial outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glioblastoma Multiforme Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glioblastoma Multiforme Treatment Market Segmental Analysis

Global Glioblastoma Multiforme Treatment Market is segmented by treatment type, end user and region. Based on treatment type, the market is segmented into chemotherapy (temozolomide, bevacizumab, carmustine, lomustine, others), radiation therapy (external beam radiation therapy (EBRT), brachytherapy), targeted therapy (monoclonal antibodies, tyrosine kinase inhibitors), immunotherapy (checkpoint inhibitors, vaccine therapy), tumor treating fields (TTF) therapy and surgery (craniotomy, biopsy). Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme Treatment market is primarily driven by several key factors. The increasing prevalence of glioblastoma, a particularly aggressive form of brain cancer, continues to spur demand for effective treatment options. Advancements in medical technology and innovative therapeutic approaches, such as targeted therapies and immunotherapy, are enhancing treatment efficacy and patient outcomes. Additionally, rising investments in research and development, along with the growing focus on personalized medicine, are fostering the introduction of new drugs and therapies into the market. Moreover, heightened awareness of glioblastoma and improved access to healthcare services are contributing to market expansion globally.

Restraints in the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme Treatment market faces several constraints that could hinder its growth. Key challenges include the high costs associated with treatment options, which may limit access for many patients. Additionally, the complex nature of glioblastoma, characterized by its aggressive behavior and resistance to conventional therapies, presents a significant barrier to effective treatment. Furthermore, a lack of robust clinical data and ongoing research may delay the introduction of new and innovative therapies. Regulatory hurdles and the need for extensive clinical trials can also impede market expansion, while the limited number of healthcare professionals specializing in this area adds to the market's challenges.

Market Trends of the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme (GBM) Treatment market is witnessing a significant trend towards increased adoption of personalized medicine, revolutionizing standard treatment paradigms. This shift leverages advancements in genetic profiling and biomarker testing, enabling healthcare providers to tailor therapies to the unique characteristics of each patient's tumor. Such precision approaches not only enhance treatment efficacy but also minimize the risk of adverse effects, reflecting a broader movement towards individualized healthcare solutions. As stakeholders invest in research and technology to develop targeted therapies, the market is poised for growth, driven by rising awareness and the potential for improved patient outcomes in GBM management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Glioblastoma Multiforme Treatment Market Size by Treatment Type & CAGR (2024-2031)

• Market Overview
• Chemotherapy
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • Others
• Radiation Therapy
  • External Beam Radiation Therapy (EBRT)
  • Brachytherapy
• Targeted Therapy
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
• Immunotherapy
  • Checkpoint Inhibitors
  • Vaccine Therapy
• Tumor Treating Fields (TTF) Therapy
• Surgery
  • Craniotomy
  • Biopsy

Global Glioblastoma Multiforme Treatment Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Research Institutes

Global Glioblastoma Multiforme Treatment Market Size & CAGR (2024-2031)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation